Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Onartuzumab
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Bevacizumab Placebo
Drug: Onartuzumab Placebo

First Posted Date: 2010-08-23

Last Posted Date: 2017-01-20

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 185

Registration Number: NCT01186991

Locations: 🇺🇸
Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States
🇺🇸
Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States
🇺🇸
St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States

and more 50 locations

Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

Phase 2

Terminated

Conditions: Gastroesophageal Adenocarcinoma
Adenocarcinoma of the Distal Esophagus
Adenocarcinomas of the Gastroesophageal Junction
Adenocarcinoma of the Proximal Stomach

Interventions: Drug: Panitumumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: 5FU

First Posted Date: 2010-08-17

Last Posted Date: 2012-12-03

Lead Sponsor: Accelerated Community Oncology Research Network

Target Recruit Count: 1

Registration Number: NCT01182610

Locations: 🇺🇸
Clopton Clinic, Jonesboro, Arkansas, United States

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

Phase 1

Completed

Conditions: Cancer of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Cancer of the Stomach

Interventions: Drug: Vandetanib
Drug: 5 Fluorouracil (FU)
Drug: Carboplatin
Drug: Paclitaxel
Radiation: External Beam Radiation Therapy (RT)

First Posted Date: 2010-08-17

Last Posted Date: 2021-01-22

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 9

Registration Number: NCT01183559

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Axitinib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-08-03

Last Posted Date: 2018-06-08

Lead Sponsor: Adil Daud

Target Recruit Count: 40

Registration Number: NCT01174238

Locations: 🇺🇸
Cutaneous Onocology Group at the Helen Dillar Family Comprehensive Cancer Center UCSF, San Francisco, California, United States

Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Myocet (Non-pegylated liposomal doxorubicin (NPLD))
Drug: Paclitaxel
Drug: Lapatinib (GW572016, Tykerb)

First Posted Date: 2010-07-29

Last Posted Date: 2016-11-02

Lead Sponsor: Prof Dirk Elling

Target Recruit Count: 81

Registration Number: NCT01172223

Locations: 🇩🇪
Sana Klinikum Lichtenberg, Berlin, Germany

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Placebo
Biological: Ramucirumab (IMC-1211B) DP
Drug: Paclitaxel

First Posted Date: 2010-07-27

Last Posted Date: 2019-09-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 665

Registration Number: NCT01170663

Locations: 🇬🇧
ImClone Investigational Site, Wolverhampton, West Midlands, United Kingdom

Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients

Phase 2

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Genexol-PM
Drug: Paclitaxel

First Posted Date: 2010-07-26

Last Posted Date: 2012-01-04

Lead Sponsor: National Cancer Center, Korea

Registration Number: NCT01169870

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3

Active, not recruiting

Conditions: Ovarian Mucinous Adenocarcinoma
Stage IIA Fallopian Tube Cancer AJCC v6 and v7
Stage IIIB Fallopian Tube Cancer AJCC v7
Ovarian Clear Cell Adenocarcinofibroma
Ovarian Serous Adenocarcinoma
Ovarian Undifferentiated Carcinoma
Stage IIA Ovarian Cancer AJCC V6 and v7
Stage IIC Fallopian Tube Cancer AJCC v6 and v7
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Paclitaxel
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2010-07-22

Last Posted Date: 2025-01-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 692

Registration Number: NCT01167712

Locations: 🇺🇸
Mid Dakota Clinic, Bismarck, North Dakota, United States
🇺🇸
Doctors Hospital, Columbus, Ohio, United States
🇺🇸
Miami Valley Hospital, Dayton, Ohio, United States

and more 562 locations

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Phase 3

Completed

Conditions: Carcinoma, Squamous Cell of the Head and Neck

Interventions: Biological: REOLYSIN
Drug: Carboplatin
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2010-07-21

Last Posted Date: 2014-11-05

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 167

Registration Number: NCT01166542

Locations: 🇺🇸
Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Wilshire Oncology Medical Group, Corona, California, United States
🇺🇸
Pasco Hernando Oncology Associates, PA, New Port Richey, Florida, United States

and more 74 locations

Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Ipilimumab, 3 mg
Drug: Ipilimumab, 10 mg
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2010-07-19

Last Posted Date: 2014-07-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT01165216

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy